$1.15
0.88%
Nasdaq, Sep 17, 01:11 pm EDT. Market open.
ISIN
US19188J3005
Symbol
COCP

Cocrystal Pharma Inc Stock price

$1.14
+0.05 4.59% 1M
+0.06 5.56% 6M
+0.16 16.45% YTD
-0.18 13.64% 1Y
-0.89 43.84% 3Y
-11.82 91.20% 5Y
-168.02 99.33% 10Y
+1.04 1,040.00% 20Y
Nasdaq, Closing price Wed, Sep 16 2026
+0.00 0.00%
ISIN
US19188J3005
Symbol
COCP
Industry

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$22.0m
Enterprise Value
$19.8m
Net debt
positive
Cash
$2.2m
Shares outstanding
13.8m
Valuation (TTM | estimate)
P/E
negative
P/S
66.5 | -
EV/Sales
60.0 | -
EV/FCF
negative
P/B
21.1
Financial Health
Equity Ratio
65.2%
Return on Equity
-
ROCE
-498.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$330.0k | $0.0
EBITDA
$-10.1m
EBIT
$-10.1m
Net Income
$-9.9m
Free Cash Flow
$-8.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
20.3%
EBIT
20.5%
Net Income
20.9%
Free Cash Flow
40.6%
Margin
Gross
-
EBITDA
-3,048.5%
EBIT
-3,063.6%
Net
-3,011.5%
Free Cash Flow
-2,410.3%
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
2.0%
Employees
11
Rev per Employee
-

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cocrystal Pharma Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Cocrystal Pharma Inc forecast:

Buy
86%
Hold
14%

Financial data from Cocrystal Pharma Inc

Jun '26
+/-
%
0.33 0.33
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.35 4.35
12% 12%
1,318%
- Research and Development Expense 6.09 6.09
22% 22%
1,845%
-10 -10
20% 20%
-3,048%
- Depreciation and Amortization 0.05 0.05
50% 50%
15%
EBIT (Operating Income) EBIT -10 -10
21% 21%
-3,064%
Net Profit -9.94 -9.94
21% 21%
-3,012%

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
8 days ago
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash.
Neutral
GlobeNewsWire
about one month ago
BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings severa...
Neutral
GlobeNewsWire
about 2 months ago
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a long...
More Cocrystal Pharma Inc News

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Dr. Lee
Employees 11
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today